Smriti Sangwan

Title: Innovations by Smriti Sangwan in Peptide Inhibitors

Introduction

Smriti Sangwan is an accomplished inventor based in Los Angeles, CA. She has made significant contributions to the field of biomedical research, particularly in the development of peptide inhibitors targeting alpha-synuclein aggregation. With a total of two patents to her name, her work is poised to impact the treatment of neurodegenerative diseases.

Latest Patents

Smriti's latest patents include "Structure-based peptide inhibitors of α-synuclein aggregation." This invention focuses on inhibitory peptides that bind to α-synuclein molecules, effectively inhibiting their amyloidogenic aggregation, cytotoxicity, and spread. The methods described in her patents offer potential treatments for conditions mediated by α-synuclein, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy (MSA).

Career Highlights

Smriti Sangwan is affiliated with the University of California, where she conducts her research and develops her innovative solutions. Her work is characterized by a strong emphasis on addressing critical health challenges through scientific advancements.

Collaborations

Some of her notable coworkers include David S. Eisenberg and Lin Jiang, who contribute to her research endeavors and collaborative projects.

Conclusion

Smriti Sangwan's innovative work in peptide inhibitors represents a significant advancement in the fight against neurodegenerative diseases. Her contributions are expected to pave the way for new therapeutic approaches that could improve the lives of many individuals affected by these conditions.